Cardiff Oncology
Natalia S. has over a decade of experience in accounting, currently serving as an Accountant at Cardiff Oncology (Trovagene, Inc.) since November 2013. Prior to this, Natalia S. worked as an Accountant Consultant at Cubist Pharmaceuticals (Trius Therapeutics) from May 2012 to November 2013. Natalia S. also held the position of Accountant III at the University of California, San Diego, from August 2011 to May 2012.
Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.